Scholarlink

Background <p>There are no prospective clinical data on the efficacy of afatinib in patients with non-small cell lung cancer (NSCLC) harboring various uncommon epidermal growth factor receptor (<i>EGFR</i>) mutations detected using next-generation sequencing. We aimed to report the efficacy and safety of afatinib in patients with NSCLC harboring uncommon <i>EGFR</i> mutations detected using next-generation sequencing.</p> Methods <p>This was a prospective single-center single-arm phase II study. Patients with histologically confirmed metastatic or recurrent NSCLC harboring uncommon <i>EGFR</i> mutations, excluding exon 20 insertion and T790M mutations detected using next-generation sequencing, were eligible. Patients received oral afatinib (40&#xa0;mg once daily). The primary endpoint was the objective response rate. The secondary endpoints were progression-free survival, overall survival, and safety.</p> Results <p>Between August 2019 and September 2022, 17 patients were enrolled. The median age was 71&#xa0;years (range, 59–80&#xa0;years; 9 males). The uncommon mutations identified were G719X (n = 4; 24%), S768I (n = 3; 17.6%), and L861Q (n = 6; 35%), and 13 other rare <i>EGFR</i> mutations were detected in 10 patients. These mutations were identified as single or compound mutations. The objective response rate for all patients was 82.4%, median progression-free survival was 11.3&#xa0;months, and median overall survival was 27.8&#xa0;months. Grade 3 or higher adverse events were diarrhea (n = 5; 29%), paronychia (n = 2; 12%), and decreased appetite (n = 2; 12%). All adverse events were manageable, and there were no treatment-related deaths.</p> Conclusions <p>Afatinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon <i>EGFR</i> mutations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing

  • 期刊论文

  • 发表日期：

    2025年7月6日

查看全文
  • Nobuaki Mamesaya,
  • Keita Mori,
  • Haruki Kobayashi,
  • Shota Omori,
  • Ryo Ko,
  • Kazushige Wakuda,
  • Akira Ono,
  • Hirotsugu Kenmotsu,
  • Tateaki Naito,
  • Haruyasu Murakami,
  • Toshiaki Takahashi

摘要

Background

There are no prospective clinical data on the efficacy of afatinib in patients with non-small cell lung cancer (NSCLC) harboring various uncommon epidermal growth factor receptor (EGFR) mutations detected using next-generation sequencing. We aimed to report the efficacy and safety of afatinib in patients with NSCLC harboring uncommon EGFR mutations detected using next-generation sequencing.

Methods

This was a prospective single-center single-arm phase II study. Patients with histologically confirmed metastatic or recurrent NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion and T790M mutations detected using next-generation sequencing, were eligible. Patients received oral afatinib (40 mg once daily). The primary endpoint was the objective response rate. The secondary endpoints were progression-free survival, overall survival, and safety.

Results

Between August 2019 and September 2022, 17 patients were enrolled. The median age was 71 years (range, 59–80 years; 9 males). The uncommon mutations identified were G719X (n = 4; 24%), S768I (n = 3; 17.6%), and L861Q (n = 6; 35%), and 13 other rare EGFR mutations were detected in 10 patients. These mutations were identified as single or compound mutations. The objective response rate for all patients was 82.4%, median progression-free survival was 11.3 months, and median overall survival was 27.8 months. Grade 3 or higher adverse events were diarrhea (n = 5; 29%), paronychia (n = 2; 12%), and decreased appetite (n = 2; 12%). All adverse events were manageable, and there were no treatment-related deaths.

Conclusions

Afatinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.